Qube Research & Technologies LTD Avadel Pharmaceuticals PLC Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$10.3 - $15.99 $551,286 - $855,832	53,523 New	53,523 $551,000
Q1 2022 May 09, 2022	SELL	$5.46 - $8.29 $874,724 - $1.33 Million	-160,206 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$7.34 - $11.18 $1.18 Million - $1.79 Million	160,206 New	160,206 $1.29 Million
Q4 2020 Feb 16, 2021	SELL	$5.03 - $7.95 $90,736 - $143,410	-18,039 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$5.02 - $8.98 $101,343 - $181,288	-20,188 Reduced 52.81%	18,039 $91,000
Q2 2020 Aug 14, 2020	BUY	$7.25 - $11.75 $196,714 - $318,812	27,133 Added 244.57%	38,227 $309,000
Q1 2020 May 15, 2020	BUY	$4.06 - $10.64 $45,041 - $118,040	11,094 New	11,094 $88,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.